Pooled rates of bleeding from the 4 RECORD trials
| . | Rivaroxaban, no. per 1000 patients . | Enoxaparin, no. per 1000 patients . | P . |
|---|---|---|---|
| Major bleeding | 3.9 | 2.1 | .08 |
| Major bleeding + surgical site bleeding | 18.0 | 13.7 | .06 |
| . | Rivaroxaban, no. per 1000 patients . | Enoxaparin, no. per 1000 patients . | P . |
|---|---|---|---|
| Major bleeding | 3.9 | 2.1 | .08 |
| Major bleeding + surgical site bleeding | 18.0 | 13.7 | .06 |
Adapted from the FDA Advisory Committee Briefing Document (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM181524.pdf; accessed October 5, 2009).